Overview

Long Term Treatment With L-DOPS

Status:
Approved for marketing
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This study is designed to supply L-DOPS (droxidopa) on a long term basis to patients with a genetic form of profound orthostatic hypotension, most commonly DBH deficiency. It also allows us to collect medical history information on this small population of patients that would allow us to determine if there are any complications from this type of treatment.
Details
Lead Sponsor:
Vanderbilt University
Vanderbilt University Medical Center
Treatments:
Droxidopa